Lupin gains ~2% on getting USFDA approval for gout, diabetes drugs

18 Dec 2023 , 11:34 AM

Lupin shares rose as much as 2.5% in early trading on December 18 after the USFDA approved its gout and diabetes drug.

At around 11.25 AM, Lupin was trading 2.09% higher at Rs 1,272.10 per piece, against the previous close of Rs 1,246.10 on NSE. 

The company has received USFDA approval for its abbreviated new drug application (ANDA) for Allopurinol tablets USP, 100 mg and 300 mg to market a generic bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zyloprim Tablets, 100 mg and 300 mg, of Casper Pharma, LLC,’ the company stated in a release.

Adult patients with signs and symptoms of primary or secondary gout (acute episodes, tophi, joint damage, uric acid lithiasis, and/or nephropathy) should be treated with Allopurinol Tablets USP, 100 mg and 300 mg.

It is used on adults and children with leukaemia, lymphoma, and solid tumour malignancies who are receiving cancer therapy that causes serum and urine uric acid levels to rise.

In another development, the business said that it has received preliminary clearance from the USFDA for its ANDA for Sitagliptin tablets USP, 25 mg, 50 mg, and 100 mg to sell a generic counterpart of Merck Sharp and Dohme Corp’s (Merck) Januvia Tablets, 25 mg, 50 mg, and 100 mg.

For feedback and suggestions, write to us at [e-mail]